Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have received an average rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $4.50.

Several research firms have commented on SGMO. Wall Street Zen cut Sangamo Therapeutics from a "hold" rating to a "sell" rating in a report on Friday. Barclays cut their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a report on Monday, April 7th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, March 18th.

Sangamo Therapeutics Trading Up 5.8%

NASDAQ SGMO traded up $0.03 on Friday, reaching $0.50. The stock had a trading volume of 5,405,844 shares, compared to its average volume of 8,799,132. The business has a 50 day moving average price of $0.63 and a 200 day moving average price of $1.16. Sangamo Therapeutics has a 1 year low of $0.30 and a 1 year high of $3.18. The company has a market capitalization of $116.63 million, a price-to-earnings ratio of -0.67 and a beta of 1.46.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $6.44 million for the quarter, compared to the consensus estimate of $7.90 million. On average, analysts anticipate that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. E Fund Management Co. Ltd. acquired a new stake in shares of Sangamo Therapeutics in the fourth quarter valued at about $25,000. JPMorgan Chase & Co. boosted its stake in shares of Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 21,793 shares during the period. PNC Financial Services Group Inc. lifted its stake in Sangamo Therapeutics by 2,319.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in Sangamo Therapeutics during the fourth quarter worth $28,000. Finally, Captrust Financial Advisors bought a new stake in Sangamo Therapeutics during the fourth quarter worth $30,000. 56.93% of the stock is currently owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.